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Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a novel early marker of acute kidney injury for
which has been shown that it can also be released from the injured myocardium. Our aim was to correlate urine
NGAL with markers of in-hospital heart failure in patients with acute ST-elevation myocardial infarction (STEMI).
Methods: We prospectively included 61 consecutive STEMI patients after primary percutaneous coronary
intervention and estimated admission and in-hospital urine NGAL, serum creatinine, troponin I, leucocytes, CRP,
N-terminal pro brain natriuretic peptide (NT-proBNP) levels and ejection fraction by echocardiography. Urine NGAL
levels were compared between patients with and without HF defined as serum NT-proBNP > 400 pmol/l and were
correlated to markers of heart failure, inflammations and of kidney function.
Results: Urine NGAL levels and CRP was significantly higher in participants with heart failure compared to those
with NT-proBNP below 400 pmol/l. Urine NGAL level of 50 ng/ml had 90 % specificity for HF, the sensitivity was
low at 25 %. Comparison of participants with NGAL levels < 50 ng/ml and ≥ 50 ng/ml at admission and after 12 h
revealed a significant difference in NT-proBNP levels, left ventricle ejection fraction, markers of inflammation and of
kidney function. Urine NGAL level was independently associated with NT-proBNP level.
Conclusions: The level of urine NGAL early after myocardial infarction is associated with NT-proBNP concentration
and even NGAL levels below 137 ng/ml, the usually reported normal cut-off value, had high specificity for HF
in our sample.
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Background
In spite of early contemporary reperfusion therapy by
primary percutaneous coronary intervention (PPCI), ST-
elevation myocardial infarction (STEMI) can lead to sys-
tolic and/or diastolic dysfunction with decreased cardiac
output, leading to further decrease in systemic and cor-
onary perfusion and activation of inflammation. It has
been shown that inflammation plays an important role
in acute heart failure (HF) after acute myocardial infarc-
tion (MI) and there is evidence for profound neutrophil
activation during acute MI with release of proinflamma-
tory markers [1, 2]. Inflammation is also important in
the process of remodeling by influencing matrix degen-
eration and fibrosis, promoting apoptosis etc. [3–5].
Neutrophil gelatinase-associated lipocalin (NGAL) is a
25 kDa glycoprotein of the lipocalin superfamily, synthe-
sized in granulocyte precursors in bone marrow during a
narrow window of their maturation. It is stored in spe-
cific granules of mature neutrophils in complex with
gelatinase [6, 7]. In recent years, NGAL has been consid-
ered mainly a predictor of acute kidney injury (AKI), be-
cause its plasma and urine levels rise before any increase
in creatinine level is encountered [8]. In addition, NGAL
has been associated with cell death, inflammation and
matrix degradation and there is increasing evidence for
enhanced systemic and myocardial expression of NGAL
after acute MI, supporting the role of inflammation in
this entity [9–12].
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The aim of our present study was to evaluate the asso-
ciation of urine NGAL early after acute STEMI with
markers of myocardial dysfunction and test its predictive
value for acute HF.
Methods
Study design and participants
We performed an observational prospective mono-
centric study with patients admitted with acute STEMI
to the Department of Medical Intensive Care (ICU),
University Medical Centre Maribor. The study was ap-
proved by the Republic of Slovenia National Medical
Ethics committee (77/01/11) and written informed con-
sent was obtained from all patients. The study protocol
conformed to the ethical guidelines of the Declaration of
Helsinki.
Consecutive patients admitted with STEMI between
April 2010 and July 2011 who had PPCI performed and
stayed at the ICU for at least 24 h were included in the
study. Criteria for STEMI were ischemic chest pain last-
ing up to 12 h plus persistent ST-elevation or new
bundle-branch block on ECG [13]; PPCI is the primary
reperfusion strategy for acute STEMI at our institution.
Exclusion criteria were prior malignancy, infectious dis-
ease, sepsis and death or discharge from the ICU in less
than 24 h.
Treatment protocol
On admission, blood samples were drawn to estimate
complete blood cell count, serum troponin I, creatinine
and lipid profile and a urine sample was collected for
estimation of urine-NGAL. Immediately after PPCI,
patients were transferred from the catheterization la-
boratory to the medical ICU for continuous ECG-
monitoring and pulse oximetry. On admission to the
ICU, a clinical examination and standard ECG were per-
formed and the patency of peripheral intravenous cath-
eter, inserted before the PPCI, was checked. In case of
hemodynamic compromise, the treating physician
assessed the need for invasive monitoring. Combined an-
tiplatelet therapy (acetylsalicylic acid and clopidogrel),
initiated either in the emergency department or by out-
patient emergency units, was continued, statins and
angiotensin-converting enzyme inhibitors were adminis-
tered to all patients unless contraindicated. After admis-
sion to the ICU, all patients were started on intravenous
saline infusions 0.5 to 1.0 ml/kg/hour, the total amount
of fluid administered depended on clinical signs of acute
pulmonary congestion [14].
Complete blood cell count, troponin I, serum creatinine,
N-terminal pro brain natriuretic peptide (NT-proBNP)
and CRP levels were estimated daily from blood samples
collected between 8.00 and 10.00 a.m. in the first two days,
later these tests were performed at the discretion of the
treating physician. For the study purposes, a urine sample
was taken for estimation of NGAL 12 h after admission
and serum creatinine level was estimated every 6 h during
the first 24 h. Two dimensional transthoracic echocardiog-
raphy was performed within the first 24–48 h. The biplane
method of disks (modified Simpson’s rule) was used to cal-
culate left ventricular ejection fraction (EF); values higher
than 55 % are considered normal [15]. Other investiga-
tions and treatment modalities were indicated by the ICU
team individually for each patient. During treatment, we
obtained data on prior known arterial hypertension, dia-
betes, dyslipidemia, prior stroke, prior MI, smoking and
physical activity.
For the purpose of this study, HF was defined as NT-
proBNP ≥ 400 pmol/l, in accordance with the European
guidelines [16]. Other estimates of heart failure were the
Kilip-Kimbal classification and ejection fraction of the
left ventricle.
Laboratory methods
The lipid profile - total serum cholesterol, HDL-cholesterol
and triglycerides were estimated by the colorimetric
method (Ektachem 250 Analyzer, Eastman Kodak
Company, Rochester, USA). Urine NGAL by the che-
miluminiscent microparticle immunoassay (CMIA)
for the quantitative determination of neutrophil
gelatinase-associated lipocalin in human urine (Abbott
ARCHITECTAnalyzer, Abbott Ireland Diagnostics
Division, Lisnamuck, Ireland; normal levels up to
131.7 ng/ml – coefficient of variability 4.6 %). Troponin I
was estimated by colorimetric-immune method (Siemens
Healthcare Diagnostics Inc., Newark, USA, normal levels
up to 0.045 μg/l). Plasma NT-proBNP levels was esti-
mated by the electrochemiluminescence immunoassay
on an Elecsys 2010 analyzer (Roche Diagnostics, nor-
mal levels up to 20 pmol/L). Complete blood cell
count was performed by automatic counter Sysmex
XE - 2100, Kobe Japan; normal levels for leukocytes
were 4 – 10 × 109/l, erythrocytes 4.2 – 6.3 × 1012/l and
platelets 140 – 340 × 109/l.
Statistical analysis
Demographic characteristic and laboratory data were
analysed using descriptive methods – frequencies, mean
with standard deviation or median with interquartile
range. Subgroup comparisons were done using χ2 test
for categorical and Student’s t-test or the nonparametric
Mann–Whitney test for numeric variables. Bivariate cor-
relations were tested by Spearmann’s coefficient (rho).
P value of 0.05 was set as the limit of statistical signifi-
cance. SPSS Statistics 18.0 (IBM ®) was used for statis-
tical analysis.
Sensitivity and specificity of NGAL concentration
for heart failure defined by elevated NT-proBNP level
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was calculated [16]. A receiver operating characteris-
tic (ROC) diagram was constructed with urine NGAL
level as the test variable and NT-proBNP level as the
state variable (Fig. 3). Area under the curve of the
constructed ROC diagram was 0.67 (95 % CI 0.52,
0.83; p = 0.02). Although the area under the curve
was relatively low, it still was considered relevant.
The cut-off of urine NGAL with 90 % specificity for
heart failure was 46.95 ng/ml, the sensitivity of this
cut-off was 25 %; the value 50 ng/ml was used in
addition to the previously established normal value
of 137 ng/ml. This 50 ng/ml cut-off was thus derived
from the same dataset as used in all other statistical
analyses.
Urine NGAL levels, markers of kidney injury and
markers of inflammation were compared between prede-
fined subgroups of patients with NT-proBNP < 400 pmol/l
and patients with NT-proBNP ≥ 400 pmol/l. Conversely,
markers of heart failure, inflammation and kidney injury
were compared in subgroups based on values of urine
NGAL. A linear regression model was constructed with
NT-proBNP as the dependent and age, gender, NGAL
level, CRP, peak creatinine and left ventricular ejection
fraction as independent variables.
Results
In total, 61 patients were included in the study, among
them 44 (72 %) men. The mean age was 63.8 years (SD
12.8 years) As shown in Fig. 1, the most prevalent risk
factor for vascular disease was arterial hypertension,
followed by dyslipidemia and diabetes.
Among the studied patients, 39 were in Kilip class I,
11 in Kilip class II, 5 in Kilip class III and 6 in Kilip
class IV as the higher class during their stay in the
ICU. The average values of analysed laboratory vari-
ables in the whole sample are presented in Table 1
and the distribution of NGAL levels stratified by
heart failure is presented in Fig. 2. There was no sig-
nificant difference between NGAL levels at admission
and after 12 h and, overall, the levels were well
below the 137 ng/ml as the usual normal cut-off
value. Only two patients had urine NGAL above
137 ng/ml both at admission and after 12 h.
We compared markers of inflammation and of cardiac
function in patients with NT-proBNP levels above and
below 400 pmol/l which was the definition for heart
failure in or study ([16]; Table 2). There was a signifi-
cant difference between subgroups in urine NGAL
levels and in markers of inflammation. The subgroups
did not differ in the amount of radiologic contrast ma-
terial infused.
As explained in the methods section, urine NGAL
50 ng/ml was established as the level with 90 % specifi-
city for acute heart failure defined by NT-proBNP
(Fig. 3). Comparison of the two subgroups with NGAL
levels < 50 ng/ml and ≥ 50 ng/ml at admission and after
12 h revealed a significant difference in NT-proBNP
levels and in ejection fraction as well as in markers
of inflammation and of kidney function between sub-
groups (Table 3). When we used 137 ng/ml as the
cut-off value, subgroups did not differ in any of the
analyzed variables.
Because NGAL has high specificity for heart failure
after STEMI in our sample, we attempted to establish
correlations between NGAL levels and markers of








% of all patients (n=61)
Fig. 1 Risk factors for vascular diseases in study participants. Legend:
MI = myocardial infarction
Table 1 Admission and in-hospital laboratory data of the
included STEMI patients
Laboratory data (mean ± SD) N = 61
Urine NGAL at admission (ng/ml) 24.5 ± 42.1
Urine NGAL at 12 h (ng/ml) 27.7 ± 42.7
In-hospital NT-proBNP (pmol/l) 565.0 ± 882.2
EF (%) 42.2 ± 12.5
Troponin I at admission (μg/l) 12.1 ± 20.5
Troponin I after 12 h (μg/l) 55.7 ± 37.0
CRP at 24 h (mg/l) 99.0 ± 54.7
Creatinine at admission (μmol/l) 102.5 ± 45.0
Creatinine at 24 h (μmol/l) 99.0 ± 54.7
Leucocyte count at 24 h (1 × 1012/l) 10.9 ± 3.9
Contrast material infused (ml) 147.2 ± 67.6
Data are presented as mean ± standard deviation
MI myocardial infarction, NGAL neutrophil gelatinase-associated lipocalin,
CRP C reactive protein, EF left ventricular ejection fraction, NT – proBNP N-terminal
pro brain natriuretic peptide
Kirbiš et al. BMC Cardiovascular Disorders  (2015) 15:49 Page 3 of 7
Fig. 2 (See legend on next page.)
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association between admission urine NGAL and in-
hospital NT-proBNP (rhos 0.34, p = 0.003) and between
admission urine NGAL and in-hospital CRP (rhos
0.22, p = 0.04). Results were similar for urine NGAL
estimated 12 h after admission (rhos 0.34 for NT-
proBNP, p = 0.003 and rhos 0.353 for CRP, p = 0.03). There
was a negative association between NGAL on admission
and EF (rhos – 0.122, p = 0.19). In a multiple linear regres-
sion model, urine NGAL levels (β = 8.91) and female
gender (β = 464.1) were independently associated with
NT-proBNP concentration, while age, peak troponin,
creatinine and CRP were not; adjusted r2 for model 0.716.
Discussion
In our sample of patients with acute STEMI we ob-
served NGAL levels below the usual normal limit
137 ng/ml in the great majority of participants. However,
higher levels of NGAL – even though below the above
stated limit – had high specificity for development of
heart failure and urine NGAL concentration was posi-
tively correlated with serum concentration of NT-
proBNP. These results suggest that elevated urine NGAL
very early after STEMI could be a marker of high risk
for acute heart failure in an individual patient and that
with regard to MI much lower concentrations of NGAL
are of significance compared to when evaluating patients
with kidney failure [17].
Urine NGAL was individually correlated with NT-
proBNP as well as with CRP and creatinine. In a
multiple linear regression model, NGAL was an inde-
pendent predictor of NT-proBNP concentration, even
though in clinical terms the association was weak. This
association and the correlation between NGAL and CRP
can be viewed as evidence for the importance of early
inflammation in acute heart failure after MI. But we
must state that NGAL has several possible sources –
most commonly is has been associated with inflamma-
tion and with kidney dysfunction – and that our study
design does not allow deductions about causality.
Damman et al. have shown that increased urine NGAL
is highly prevalent in patients with chronic HF and,
similarly to our results, positively associated with in-
creased levels of NT-proBNP [18]. Other authors have
demonstrated that in patients with chronic HF of ische-
mic origin with normal renal function, serum NGAL
levels were markedly increased in comparison to con-
trols and this increase independently correlated with
New York heart Association (NYHA) class and the esti-
mated glomerular filtration rate [19]. It has also been
demonstrated that plasma NGAL strongly predicted
mortality in patients with chronic heart failure with and
without chronic kidney disease [20]. Our results suggest
(See figure on previous page.)
Fig. 2 The distribution of urine neutrophil gelatinase-associated lipocalin (NGAL) concentration at admission (a) and 12 h after admission (b) and
its relation to serum N-terminal pro brain natriuretic peptide (NT-proBNP) concentration. a Urine NGAL levels at admission. b Urine NGAL levels
12 h after admission. Legend: NGAL = neutrophil gelatinase-associated lipocalin; NT – proBNP = N-terminal pro brain natriuretic peptide
Table 2 Comparison of subgroups with heart failure and with
no heart failure as defined by N-terminal pro brain natriuretic
peptide level (NT-proBNP)







EF at 24–48 h (%) 48.1 ± 7.8 31.3 ± 11.9 <0.01
Urine NGAL at admission (ng/ml) 14.8 ± 19.2 45.0 ± 65.2 <0.01
Urine NGAL at 12 h (ng/ml) 15.5 ± 18.3 53.8 ± 63.6 <0.01
Troponin I at admission (μg/l) 7.2 ± 13.0 22.5 ± 28.7 <0.01
Creatinine at 24 h (μmol/l) 83.7 ± 28.9 134.0 ± 79.9 <0.01
CRP at 24 h (mg/l) 21.3 ± 23.3 59.5 ± 74.9 <0.01
Leucocytes at 24 h (1 × 1012/l) 10.1 ± 3.0 12.6 ± 5.1 <0.01
Amount of contrast material (ml) 142.0 ± 67.3 160.3 ± 69.6 NS
Data are presented as mean ± standard deviation
MI myocardial infarction, NGAL neutrophil gelatinase-associated lipocalin,
CRP C reactive protein, EF left ventricular ejection fraction, NT-proBNP N-terminal
pro brain natriuretic peptide
Fig. 3 The receiver operating characteristic (ROC) curve for
determination of cut-off value and predictive values of neutrophil
gelatinase-associated lipocalin (NGAL) in urine for heart failure in
patients after myocardial infarction
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that NGAL is also associated with markers of acute HF
also in the setting of STEMI and this in probably inde-
pendent of kidney function. Previous (chronic) heart fail-
ure is a possible confounding factor, but unfortunately,
we did not have reliable enough data about past cardiac
function in our participants.
Kidney damage is another possible cause of elevated
NGAL. After STEMI, kidney injury may be the conse-
quence of different mechanisms including systolic dys-
function, nephrotoxicity of contrast material used during
PPCI, other nephrotoxic drugs, activation of sympathetic
and renin-angiotensin-aldosterone system, inflammation
and oxidative stress. NGAL can be released by activated
neutrophil, epithelial and endothelial cells, smooth
muscle cells and cells in in atherosclerotic plaques
[19, 21]. Aghel et al. revealed that patients who de-
veloped worsening renal function during hospitalization
had significantly higher median admission serum NGAL
levels (admission NGAL levels ≥ 140 ng/ml) [22]. In our
patients, the mean creatinine level was near normal and
no one required renal replacement therapy. The amount
of contrast material did not differ between patients with
and without heart failure nor between patients with
NGAL levels above and below 50 ng/ml and we therefore
assume that kidney failure is unlikely the sole explanation
for elevated NGAL in patients with heart failure in our
sample. Palazzuoli et al. showed that NGAL levels
above 130 ng/ml predicted not only renal injury, but
also an overall risk for cardiac events [17]. According
to our data, the NGAL levels predicting heart failure
are even lower.
Study limitations
Several limitations may influence our results. We studied
urine NGAL concentrations, which may follow a differ-
ent timeline than serum concentration and have a differ-
ent relationship with kidney damage compared to serum
concentration. We also had no data on prior heart
failure, which has been shown to influence NGAL levels
[18]. Importantly, the cut-off value of urine NGAL with
high specificity for HF (50 ng/ml) was derived from the
analyzed sample itself and this will have to be verified in
other, larger samples. Patients who were discharged from
the ICU within 24 h were excluded from the study and
this diminished the number of participants with a pos-
sible bias towards more severe cases.
Conclusions
The level of urine NGAL early after myocardial infarc-
tion is associated with NT-proBNP concentration and
even NGAL levels below 137 ng/ml, the usually reported
normal cut-off value, had high specificity for HF in our
sample. The mechanism of urine NGAL increase after
STEMI and its potential value as a predicting factor for
acute HF should be investigated in further studies.
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